

blinklab

3 April 2024

BlinkLab to List on the ASX

- BlinkLab Limited shares to commence trading on the Australian Securities Exchange (ASX) on 4 April 2024 at 12:00pm (AEDT) under the ticker code BB1.
- The oversubscribed IPO raised A\$7m at \$0.20 per share.
- Capital raised will be used to progress smartphone-based autism diagnostic test into FDA registrational study, initiate further clinical studies in other programs including ADHD as well as continue to advance in-house AI/ML algorithms.

BlinkLab Limited (ASX:BB1) (“**BlinkLab**” or the “**Company**”), a company focused on developing new smartphone-based AI-powered mental healthcare solutions, is excited to announce its upcoming listing on the Australian Securities Exchange (ASX) on 4 April 2024 at 12:00pm AEDT 9:00am AWST under the ticker code BB1. BlinkLab, a company started by neuroscientists at Princeton University, over the past several years has fully developed a smartphone-based test for early diagnosis of autism, ADHD, and other neurodevelopmental conditions. Funds raised will be used to finalize an FDA Class II medical device registration study in autism in partnership with leading US university hospitals.

BlinkLab Chairman, Brian Leedman, said: “I believe BlinkLab is the next groundbreaking venture in digital healthcare. Our innovative approach leverages the power of smartphones, AI and machine learning to deliver autism screening tests specifically designed for children as young as 18 months old. This will aid healthcare providers to identify these children at a much younger age than presently available providing a pathway to effective treatment and better outcomes for the child and their families. This cutting-edge digital technology is poised to capture the imagination of major industry players, eager to embrace transformative solutions in healthcare.”

The BlinkLab Test combines a smartphone’s ability to deliver stimuli and acquire data using computer vision with a secure cloud-based platform for data storage and analysis. In the experiments, each audio and/or visual stimulus is presented with millisecond-precise control over parameters such as timing, amplitude, and frequency. To maintain participant attention, an entertaining video of choice is shown with normalized audio levels. Participants’ responses are measured by the smartphone’s camera and microphone and are processed in real time using state-of-the-art computer vision techniques, fully anonymized, and transferred securely to the analysis portal. There, BlinkLab’s in-house AI/machine learning algorithms then perform clustering and statistical analysis to identify the predictive value of the test in a particular data set. This AI-based

www.blinklab.org | info@blinklab.org | BLINKLAB LIMITED ACN 652 901 703
Level 5, 126-130 Phillip Street, Sydney NSW 2000

For personal use only


blinklab

smartphone based platform is designed to be used under supervision of medical healthcare practitioners.

Company's previous clinical trials have shown an impressive success rate in the diagnosis of autism, achieving sensitivity of 85 percent and specificity of 84 percent. These trials are very similar to regulatory studies required by US FDA and have shown a much higher accuracy of BlinkLab Test compared to currently approved products that do not use computer vision and a smartphone.

Our patented technology: neuroscience on a smartphone

Minuscule facial reflexes, evoked by our app, generates a digital biomarker for autism.



BlinkLab's AI-driven digital platform will address a significant unmet need for cost-effective and precise diagnostic alternatives.

BlinkLab team has experienced management and leading experts in the field of machine learning, autism, and brain development, bridging the most advanced technological innovations with groundbreaking scientific research. These include Princeton University Professor Sam Wang, a co-founder of BlinkLab, who is recognized as a global key opinion leader in the field of brain research and autism. Professor Wang serves as Chair of Blinkab's Independent Advisory Board.

BlinkLab Co-founder and Chief Executive Officer, Henk-Jan Boele, commented on the listing: "Today marks a milestone for BlinkLab as we list on the ASX, which will be a new chapter in our journey to bridge the translational gap between groundbreaking science and everyday lives of people. Since the beginning as a Princeton University startup several years ago, our mission has always been to harness the power of fundamental neuroscience using mobile technology in order to improve the early diagnosis of neurodevelopmental conditions in children.

www.blinklab.org | info@blinklab.org | BLINKLAB LIMITED ACN 652 901 703
Level 5, 126-130 Phillip Street, Sydney NSW 2000

For personal use only

blinklab

This listing not only validates our team's dedication, excellence, and hard work but also opens exciting opportunities for us to expand our reach and impact. We are deeply committed to obtaining regulatory clearances for BlinkLab to make neuroscience accessible and beneficial for all. Our ASX listing is a significant step towards realizing this vision. We look forward to the support of our new shareholders and the broader community as we continue to innovate and bring our vision to life."

NEXT STEPS

For the BlinkLab Device to be used as a clinical aid in the diagnosis of autism, the Company will need to complete a pivotal registrational study. If successful, the Company will apply for FDA 510(k) registration and seek commercial reimbursement for the BlinkLab Test. The registrational study intends to recruit up to 500 subjects. Enrolments for this study will start during the second half of 2024, with study completion expected by mid-2025. The Company will also be initiating studies in other indications including ADHD, schizophrenia, and others with a view of preparing these tests for future regulatory studies.

BlinkLab envisions a future where AI-powered tools become widely available and accessible to everyone. These tools will not only provide top-notch diagnosis, but also precisely and dynamically track personalized treatments based on the tools' predictions, all while maintaining the highest level of clinical accuracy and reliability. Also, binary classifiers are useful if a condition is already suspected, but we believe that the ideal scenario will be to distinguish autism from conditions such as ADHD, schizophrenia, anxiety, depression, and speech delays. As we continue to advance our supervised AI/ML model we expect to accumulate new intellectual property and industry interest in our data science and automated diagnostics techniques.

This announcement has been approved by the Board of Directors.

For further information please contact:

Henk-Jan Boele
Chief Executive Officer
henkjan@blinklab.org
M: +31 71 799 6194

Brian Leedman
Non-Executive Chairman
brian@blinklab.org
M +61 (0) 412 281 780

blinklab

About BlinkLab Limited

BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.